Monday, April 18, 2022 8:24:05 AM
Regen's only approved IND lapsed with the FDA and is no longer is valid. After several refiles due to lacking data (the problem with having poor management) Regen finally got HemaX approved to start the FDA Clinical trial process and proceed to Phase 1 trials.
The problem was that Koos had no funding to put together the expensive Phase 1 trail which tests for safety.
The critical step was the death knell for HemaX.
So what did Konman Koos do? He abandoned it and decided to focus on DCellVax.
He tried submitting it to the FDA but the FDA, once again, kicked the submission back because Regen failed to provided the minimum data needed. Koos then hired Dr. Kesari to help with the submission. Even Dr. Kesari help was not enough as the FDA still wanted more info before giving DCELLVAX the nod for approval to start the clinical phase testing.
Bad management = bad results and Koos is one bad CEO.
That's a fact and still a fact today.
And patents don't equal guaranteed success or a cure for cancer.
If it did, why then has no one of significance come to help fund Regen in a legit way to get the drugs into the testing phase?
REGEN is just another OTC SCAM stock run by one guy who has used the loose OTC policies to enrich himself while he has screwed over his investors, partners, and vendors.
Just ask Chemdiv. Koos had to pay them $800K to avoid getting his clock cleaned in court.
FACTS are stubborn things
FEATURED Integrated Ventures Files Q3/2024 With Mining Revenues Of $1,983,250 And Positive Earnings Of $0.05 Cents Per Share • May 15, 2024 10:30 AM
Swifty Global Announces Impressive Financial Results for Q1 2024 • DRCR • May 15, 2024 10:25 AM
Branded Legacy Inc. Invites Shareholders to Celebrate Milestones at Open House: Announces Share Buyback and Commitment to Authorized Share Count • BLEG • May 15, 2024 8:30 AM
Alliance Creative Group (ACGX) Releases Q1 2024 Financial and Disclosure Report with an 88% increase in Net Income from Q1 2023 to Q1 2024 • ACGX • May 15, 2024 8:30 AM
Category V Biotech, Inc. Announces Letter of Intent to Acquire Genetic Networks, Expanding into Biotechnology Sector • CATV • May 15, 2024 8:00 AM
POET Announces Design Win and Collaboration with Foxconn Interconnect Technology for High-speed AI Systems • POET • May 14, 2024 10:09 AM